Flexing their muscle
Before Medtronic imploded the company was ruthless when it came to IP. Hence the reason we are not surprised that Insulet now the market leader is doing the same thing. As everyone knows there are lots of Omnipod wannabes yep everyone wants a patch pump. Hence the reason this caught our eye: According to the Juve Patent site- “Italian company Menarini Diagnostics may no longer sell its insulin pump GlucoMen Day Pump...
The Silence makes the most noise.
This really should shock no one but it looks as though Medtronic Diabetes is about to undergo a reduction in force. Like Tandem Medtronic is having a tough time competing with Insulet. Like Tandem Medtronic management can’t adapt to the changing landscape of the insulin pump world. Like Tandem Medtronic foolishly believes that new products will come along and save the day. Meanwhile back in the Boston area the Bruins are...
What would it be like?
Now that Novo Nordisk has followed Lilly in lowering insulin prices Sanofi will surely follow and everyone can do the happy dance. The patient advocates can claim victory and set their sights on non-diabetic patients stealing from patients with diabetes. We on the other hand prefer to look ahead as the world is changing before our eyes. These cuts in the price of insulin are just the first step more...
The Class System
Before everyone gets too involved in their brackets it’s time to examine an issue that’s impacting the future of diabetes management. Unfortunately, this is not a new issue it’s just evolved over the years. For as long as we’ve been publishing there has been a very noticeable class warfare going on within the diabetes community. This goes well beyond Type 1 patients looking down on Type 2 patients believing that...
This is just the beginning.
As we predicted after their disastrous earnings call Tandem has implemented a significant reduction in force. While the exact numbers have not been made public, we believe this is just the first in a series of cost reductions. We also anticipate that it won’t be long before more changes come along including a new senior management team. Simple put the mistakes made by management have come home to roost and...
The possible play for Abbott
Now that Abbott has “cleared” the AID hurdle for Libre questions abound as to what’s next. As we noted yesterday Abbott could buy either Insulet or Tandem. Keep in mind Abbott has two goals here; increase Libre sales and stymie Dexcom from gaining more users. Abbott has also made it clear they are not opposed to acquisitions. The question becomes are Insulet and Tandem the only options here. Given that 61%...
The real cage match.
This really shouldn’t surprise anyone, but last Friday Abbott filed suit against Dexcom over the G7. Frankly this suit is not a surprise as it’s Abbott and Dexcom who are involved in a real-world cage match. IP suits are all part of the game, a game in which the only winners are the patent attorneys and expert witnesses. These suits aren’t ever settled quickly which means it likely will years...